VR Adviser’s Cardiff Oncology CRDF Stock Holding History

VR Adviser’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,271,985	Closed	-$18M	–	27
2020 Q3	$18M	Buy	+1,271,985	New	+$8.4M	3.53%	9

Other funds holding CRDF

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

VR Adviser's CRDF Position: Q4 2020 in Review

VR Adviser sold out of Cardiff Oncology (CRDF) in Q4 2020, closing a stake of 1,271,985 shares — an estimated $18M sold.

VR Adviser first reported a position in CRDF in Q3 2020 and held it in 1 quarter. The position peaked at $18M in Q3 2020. 82 funds tracked by Wall St. Rank hold CRDF as of Q4 2020.

VR Adviser reported no remaining Cardiff Oncology position as of Q4 2020 after selling out during the quarter.
VR Adviser sold 1,271,985 Cardiff Oncology shares in Q4 2020, an estimated $18M.
VR Adviser first reported a position in Cardiff Oncology in Q3 2020 and held it in 1 quarter.
VR Adviser's Cardiff Oncology position peaked at $18M in Q3 2020.
82 funds tracked by Wall St. Rank held Cardiff Oncology as of Q4 2020.

Based on VR Adviser's 13F filing for Q4 2020, filed 12 Feb 2021.